Sign in

CIK 0001783328

  • Non-accelerated filer
  • Smaller reporting company
  • Emerging growth company

TScan Therapeutics, Inc.

Sign in to watch
Ticker
TCRX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
825282075
Phone
+1 857-399-9500
Business address
830 WINTER STREET, WALTHAM, MA, 02451
  1. 4 Derivatives Options or other derivatives
  2. 4 Derivatives Options or other derivatives
  3. 4 Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Open-market buy Chief Executive Officer bought 25,000 shares at an average $3.59 ($89,821)
  7. 4 Open-market buy Director bought 1,359,792 shares at an average $1.88 ($2,559,154)
  8. 4 Open-market buy Chief Financial Officer bought 15,000 shares at $3.40 ($50,982)
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Option exercise Chief Executive Officer acquired 48,670 shares (option exercise)
  15. 4 Open-market buy Chief Legal Officer bought 4,716 shares at $7.48 ($35,255)
  16. 4 Open-market buy Chief Financial Officer bought 5,000 shares at $6.32 ($31,585)
  17. 4 Open-market buy Chief Scientific Officer bought 5,000 shares at an average $6.22 ($31,097)
  18. 4 Open-market buy Chief Financial Officer bought 5,885 shares at $8.48 ($49,925)
  19. 4 Derivatives Options or other derivatives
  20. 3 Insider Initial Statement of Ownership

Page 5 of 6 · 119 filings